Use fundamental data analysis to check all available reported financial drivers of D N A to find out if markets are at this moment mispricing the company. We found twenty-three available fundamental indicators for D N A Biomedical Solutions Ltd which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all D N A fundamentals including its Cash and Equivalents, Beta, Current Liabilities, as well as the relationship between Cash Flow from Operations and Retained Earnings . Use D N to protect against small markets fluctuations. The stock experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of D N to be traded at S23.71 in 30 days
D N Company Summary
D N competes with Kamada Ltd, Compugen Ltd, Evogene Ltd, and BioLight Life. D.N.A Biomedical Solutions Ltd. develops and commercializes laser spectrometry-based trace detection systems in Israel. D.N.A Biomedical Solutions Ltd. was founded in 2004 and is based in Ramat Gan, Israel. D N operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange.
D N Current Asset vs Total Asset
D N A Biomedical Solutions Ltd is rated # 5 in current asset category among related companies. It is rated # 5 in total asset category among related companies fabricating about 1.62 of Total Asset per Current Asset.
D N A Systematic Risk